Law360, New York ( March 12, 2015, 11:12 AM EDT) -- On Feb. 25, 2015, nearly two years after argument, the South Carolina Supreme Court directed entry of a $136 million judgment against Janssen Pharmaceuticals Inc.[1] These civil penalties stemmed from a suit brought by the state's attorney general relating to Risperdal, Janssen's "atypical," or "second generation," anti-psychotic medication, which has been on the market since 1994. The court found Janssen's communications to doctors had a "tendency to deceive," even though there was no evidence that any doctor had been deceived or any patient harmed....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.